Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CellPro looks past its quickie divorce

CellPro Inc. and Corange International Ltd. wasted no time in settling their differences over the size of the equity payment Corange owed CPRO, thus allowing them to exit an alliance that neither any longer wanted.

Corange owed a $60 million equity payment in April, based on the 1993 agreement to develop

Read the full 502 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers